2020 Annual Meeting Video Library
Annual Meeting Video
Inaugural Virtual Visiting Clawater Professor
Ashish Kamat, MD, MBBS
Poster Sessions – Translational
Mutational signature modelling in vitro recapitulates bladder cancer initiation
Investigating sexual dimorphism in the tumour immune microenvironment of non-muscle invasive bladder cancer
Proteins Involved in Mitochondrial Biogenesis, Dynamics and Respiratory Complex I Activity are Increased in Bladder Cancer and are Inversely Associated with Tumor Aggressiveness
Organotypic model and in vitro modeling or urothelial carcinoma give different cellular responses to proteinase activated receptor (PAR) agonism and antagonism
An evaluation of single-sample tumor subtype classification methods
Cytotoxic and genotoxic effects of epigenetic inhibitors on bladder cancer cells
Tumor Immune Microenvironment in Responde to Radiotherapy vs BCG in a Murine Model of Bladder Cancer
An exploratory proteomic study delineating the local and systemic immune-oncologic profile of urinary bladder cancer patients
RBM10: The role of splicing factor in urothelial homeostatis and tumorigenesis
FBXW7 loss of function contributes to worse overall survival and associates with MYC accumulation in muscle invasive bladder cancer
The potential for designing urothelial carcinomas using pluripotent stem cell-based systems
Genomic and transcriptomic characterization of metastatic urothelial carcinoma
Improving oncolytic virotherapy efficacy using target therapies against molecules of cell cycle control
Multiplex immunofluorescence to assess the tumor microenvironment in bladder cancer
Radiosensitization of bladder cancer cells via short-chain fatty acids and/or other metabolites produced by the gut microbiota
Regulation of PPARg expression in luminal muscle invasive bladder cancer
Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders
Poster Sessions – Clinical
Role of blue light cystoscopy in detecting invasive bladder tumor: Data from multi-institutional registry
Role of CA125 CA19-9 & CEA in predicting outcome following neoadjuvant chemotherapy (NAChT) in muscle invasive bladder cancer (MIBC)
Age is associated with response to immune checkpoint blockade in advanced urothelial carcinoma
Correlation between BMI, Diabetes Mellitus, and Outcomes in Patients Treated with BCG Immunotherapy for Non-Muscle Invasive Bladder Cancer
Divergent immunol correlates of PD-L1 scoring algorithms in muscle-invasive urothelial bladder cancer correlate with different patient outcomes
Predictive and prognostic performance of IHC3-Uro immunohistochemistry-based molecular subtyping in muscle-invasive bladder cancer
Transition of ANXA10 expression is a useful dianostic and prognostic marker in upper tract urothelial carcinoma
Restaging Transurethral Resection of HG Ta Urothelial Carcinoma: A Risk-Adapted Approach
Cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial
Measureable Absolute Basophil Count is Associated with Progression to Muscle Invasive Disease in Patients with High-Grade Non-Muscle Invasive Bladder Cancer
CtDNA as a Predictor of Outcome
CBI after Turbt for Prevention of NMBIC Recurrence: A Systematic Review
Lytic Effects of Water on Bladder Cancer Cell Lines: Implications for CBI for Reduction of Recurrence
Protective effect of BCG bladder instillations on pneumonia?
Comparing Cost of Radical vs Partial Cystectomy for Patients Diagnosed with Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care
Geographic Distribution of Racial Differences in Bladder Cancer Mortality in the United States: A Nationwide Population-Based Study
Long-Term Outcomes and Cost Among BCG-treated High Risk Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting
Use of Psychotropic Drugs Among Bladder Cancer Patients in the United States
Abstract Sessions – Translational Track
Molecular Profiling of Post-Pembrolizumab Muscle Invasive Bladder Cancer (MIBC) Reveals Unique Features that may Inspire NEw Sequential Therapies in Pathological Non-Responders
Recombinant BCG Overexpressing STING Agonist Elicits Trained Immunity and Improved Antitumor Efficacy in Non-Muscle Invasive Bladder Cancer
Molecular Correlates of Cisplatin-based Chemotherapy Response in Muscle Invasive Bladder Cancer by Integrated Multi-omics Analysis
NER Pathway Deficiency in Bladder Cancer
Recurring Urothelial Carcinomas are Clonal but Incompatible with a Direct Relationship
Abstract Sessions – Basic Research Track
Development and Characterization of a Novel Autochthonous Semi-spontaneous Bladder Cancer Model by Pathological Examination, Single Cell RNA Sequencing and Proteomic Profiling
Cisplatin-Based NAC
Identification of New Driver and Passenger Mutations within APOBEC-Induced Hotspot Mutations in Bladder Cancer
STAG2 and PPARg as Drivers of Luminal-Type Bladder Cancer
Extraction-Free Comprehensive Transcriptome Squencing of Carcinoma In-SITU is Highly Feasible and Insightful in Non-Muscle Invasive Bladder Cancer
Abstract Sessions – Clinical Track
Germline-somatic Interactions in the Bladder Cancer Genome
Specific Genetic Susceptibility Patterns of the Urothelial Bladder Cancer Taxonomic Subtypes
Drug Repurposing for Bladder Cancer Driven by Patients’ Proteomic Signatures
Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guerin VPM1002BC in patients with non-muscle invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14
Impact of Upper Tract Urothelial Carcinoma on Outcomes of Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin
State of the Art Talks
Keynote: Improving Immune Checkpoint Inhibitor Therapy in Cancer
The Ariadne’s Thread of FGFR3